|
Market Closed -
Nasdaq
00:00:00 03/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.3474 USD | -2.96% |
|
-2.42% | -78.42% |
| 08-24 | Maxim Downgrades NexGel to Hold From Buy | MT |
| 08-21 | Nexgel, Inc. Forms Special Committee to Oversee Comprehensive Strategic Review and Value Creation | CI |
| Market Cap | 3.39M 2.92M 2.75M 2.51M 4.69M 320M 4.72M 32.58M 12.64M 164M 12.72M 12.44M 537M | P/E 2026 * |
-0.37x | P/E 2027 * | -1.58x |
|---|---|---|---|---|---|
| Enterprise Value | 3.39M 2.92M 2.75M 2.51M 4.69M 320M 4.72M 32.58M 12.64M 164M 12.72M 12.44M 537M | EV / Sales 2026 * |
0.21x | EV / Sales 2027 * | 0.14x |
| Free-Float |
85.98% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : NEXGEL, Inc.
| 1 day | -2.96% | ||
| 1 week | -2.42% | ||
| Current month | -3.18% | ||
| 1 month | -16.31% | ||
| 3 months | -40.21% | ||
| 6 months | -69.26% | ||
| Current year | -78.42% |
| 1 week | 0.33 |  | 0.38 |
| 1 month | 0.3 | | 0.59 |
| Current year | 0.3 | | 1.9 |
| 1 year | 0.3 | | 2.89 |
| 3 years | 0.3 | | 5.1 |
| 5 years | 0.3 | | 5.1 |
| 10 years | 0.3 | | 5.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Kieser
CEO | Chief Executive Officer | 59 | 21/08/2026 |
Ian Blackman
DFI | Director of Finance/CFO | 58 | 27/04/2026 |
Gregory J. Robb
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jerome Zeldis
BRD | Director/Board Member | 76 | 01/04/2020 |
Steven Glassman
CHM | Chairman | 61 | - |
| Director/Board Member | 55 | 31/07/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.96% | -2.42% | -85.22% | -86.21% | 3.39M | |
| +0.01% | -2.47% | +57.79% | +108.23% | 1,034B | |
| +1.48% | +1.93% | +54.56% | +71.49% | 663B | |
| +0.67% | -0.45% | +23.50% | +76.60% | 462B | |
| +2.31% | -1.73% | +32.73% | +38.83% | 344B | |
| -0.24% | +5.17% | +27.16% | +47.23% | 307B | |
| +1.62% | +0.73% | -0.06% | +14.15% | 251B | |
| +1.08% | +0.57% | +54.34% | +72.51% | 239B | |
| +2.05% | +4.08% | -15.73% | -53.11% | 207B | |
| -0.21% | +1.03% | +32.74% | +95.19% | 186B | |
| Average | +0.49% | -0.87% | +18.18% | +38.49% | 369.34B | |
| Weighted average by Cap. | +0.73% | -0.84% | +38.51% | +67.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.79M 13.62M 12.83M 11.69M 21.85M 1.49B 22.01M 152M 58.95M 762M 59.28M 57.99M 2.5B | 24.27M 20.94M 19.72M 17.97M 33.59M 2.29B 33.84M 233M 90.61M 1.17B 91.13M 89.13M 3.85B |
| Net income | -8.33M -7.18M -6.77M -6.17M -11.52M -787M -11.61M -80.12M -31.09M -402M -31.27M -30.59M -1.32B | -2.31M -1.99M -1.88M -1.71M -3.2M -218M -3.22M -22.24M -8.63M -112M -8.68M -8.49M -367M |
| Net Debt | - | - |
Employees
19
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/09/26 | $0.3474 | -2.96% | 152,734 |
| 01/09/26 | $0.3580 | -0.22% | 171,989 |
| 31/08/26 | $0.3588 | +1.93% | 188,471 |
| 28/08/26 | $0.3520 | +0.60% | 196,120 |
| 27/08/26 | $0.3499 | -1.71% | 331,263 |
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3474
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NXGL Stock
Select your edition
All financial news and data tailored to specific country editions
